GLP-1 Receptor Agonists Show Favorable Thyroid Safety in Prediabetes and T1D, Modestly Increase Nonmalignant Outcomes in T2D
Background
The widespread use of Glucagon-like peptide-1 receptor agonists (GLP-1RAs) for type 2 diabetes and obesity has raised questions about their thyroid safety profile. Preclinical rodent studies have shown concerns regarding C-cell hyperplasia, yet clinical evidence across different glycemic states like prediabetes, type 1 diabetes (T1D), and type 2 diabetes (T2D) has been inconsistent and lacking. This gap in understanding the diabetes-type-specific associations between GLP-1RA therapy and various thyroid outcomes, including thyroid dysfunction, autoimmune thyroiditis, nontoxic goiter, and thyroid cancer, necessitated a large-scale real-world investigation.
Study Design
Researchers conducted a real-world, retrospective target-trial emulation using electronic health records from the TriNetX US Collaborative Network. They identified adults with prediabetes, T1D, or T2D who initiated GLP-1RAs. Active comparator groups included usual care and sodium-glucose cotransporter two inhibitors (SGLT2i). Propensity score matching with extensive covariate adjustment was applied to minimize bias. Participants were followed for incident thyroid outcomes for up to 5 years, with sensitivity and subgroup analyses performed to ensure robustness. Primary endpoints included thyroid dysfunction, autoimmune thyroiditis, nontoxic goiter, and thyroid cancer.
Results
Across different glycemic states, GLP-1RA therapy exhibited distinct thyroid safety patterns. In individuals with prediabetes and T1D, GLP-1RA use was associated with reduced risks of both thyroid dysfunction and all-cause mortality, suggesting potential metabolic or immunomodulatory benefits in these populations. By contrast, among individuals with T2D, GLP-1RA exposure was linked to modest increases in autoimmune thyroiditis and nontoxic goiter. This effect was particularly noted in subgroups with obesity or without hypertension. Importantly, the study provided reassuring evidence regarding long-term endocrine safety:
No increased risk of thyroid cancer was observed in any glycemic state (prediabetes, T1D, or T2D) during the follow-up period.
Key Findings
- GLP-1RA use associated with reduced risks of thyroid dysfunction in prediabetes and T1D.
- GLP-1RA use linked to reduced all-cause mortality in prediabetes and T1D.
- GLP-1RA exposure modestly increased autoimmune thyroiditis in T2D.
- GLP-1RA exposure modestly increased nontoxic goiter in T2D, particularly with obesity.
- No increased risk of thyroid cancer observed in any glycemic state (prediabetes, T1D, T2D).
Why It Matters
This large-scale real-world study offers crucial insights for peptide users, biohackers, and clinicians regarding the thyroid safety of GLP-1RAs. The absence of an elevated thyroid cancer risk across all glycemic states provides significant reassurance, addressing a long-standing concern stemming from preclinical data. However, the findings suggest a need for nuanced patient counseling: while GLP-1RAs appear favorable for thyroid health in prediabetes and T1D, individuals with T2D, especially those with obesity, might experience modest increases in nonmalignant thyroid conditions like autoimmune thyroiditis or nontoxic goiter. This implies that monitoring for these specific nonmalignant outcomes might be prudent in T2D patients on GLP-1RAs, potentially influencing personalized treatment strategies and follow-up protocols.
glp-1ra
thyroid-safety
prediabetes
type-1-diabetes
type-2-diabetes
autoimmune-thyroiditis